A firm based invests strategically on behalf of a global pharmaceutical company. The firm will invest mostly in therapeutics, and a bit in digital health.
The firm is interested in life science opportunities globally, and expects to make 3-4 new investments per year. The firm typically invests about $15M over the life of an investment for therapeutics companies, and slightly less for digital health companies. The fund is typically a lead investor, and participates in syndicates with other investment firms. The firm does not attach rights or options to equity investments – the firm considers opportunities globally but focuses on Europe, Middle East and North America.
The firm is strategically mandated to invest in opportunities beyond the parent company’s core areas of business. The fund seeks to invest in companies with therapeutic platform technologies and digital health. The firm is only interested in novel technologies; while the fund will consider investing in any form of therapeutic technology (esp. new therapeutic modalities, such as cell / gene therapy), regenerative medicine, cell therapies and gene therapies are the areas of greatest interest. The fund is focused on investing in oncology (particularly immuno-oncology and immunomodulation), tissue regeneration (stem cells, NCEs, biologics), anti-infectives with novel MOA, and microbiome; within digital health, the firm is interested in patient care management (i.e. diagnosis and monitoring of disease, prevention of onset and progression of disease including digital biomarkers, population management), medication adherence, digital companion therapy, and digital therapy as stand alone. The firm will also consider opportunities in other indication areas outside of the aforementioned key areas of interest. The firm generally invests in preclinical assets.
The firm invests in technologies of strategic importance the parent company. The firm only invests in privately held companies. The firm typically does not invest in single asset opportunities; only companies with multiple pipeline assets are of interest. The firm is often the first outside investor in a company, and prefers to invest in opportunities where the firm’s allocation can secure a meaningful stake in the company (a board seat is a requirement).
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment